| March 1, 2013 | News for the transfusion medicine and cellular therapy community |
 |  |
| Top Story |  |  |
|
- Public health, medical research to suffer from sequestration
Sequestration will have a major impact on public health and medical research, both of which have been restricted by years of underfunding and cuts. "These cuts are going to have a real impact," Washington state Health Secretary Mary Selecky said. "In the next six to eight weeks, we're going to have to say we're closed on Fridays or we can't provide this or that service anymore." Researchers who depend on NIH grants also have expressed concern that their work will have to be scaled back. Los Angeles Times (tiered subscription model)
(2/27)     
| Science & Health | | |
|
- Trial compares heart implant, warfarin for AF patients
In patients with atrial fibrillation, Boston Scientific's Watchman heart implant performed better than the anticoagulant warfarin in terms of quality-of-life indicators after one year, according to a study published in the Journal of the American College of Cardiology. The study, however, also found that patients who had the implant had a higher risk for serious bleeding. MassDevice.com (Boston)
(2/28)
- Country-by-country approach can control malaria, study suggests
Research shows that a country-by-country approach to fighting malaria can be remarkably successful at keeping the disease at bay. Urbanization and improved living conditions, among other factors, have helped countries eliminate the disease, according to University of Southampton geography professor Andrew Tatem. "Still, a child dies of malaria every 45 seconds, especially in sub-Saharan Africa," he noted. The Gainesville Sun (Fla.)
(2/22)
| Emerging Trends | | |
|
| Industry News & Practice | | |
|
- Baxter submits hemophilia drug for FDA approval
Baxter International filed a biologics license application with the FDA for approval to use FEIBA NF Nanofiltered and Vapor Heated, its anti-inhibitor coagulant complex treatment, in patients with hemophilia A or B and inhibitors. The application was based on a late-stage trial that found routine prophylactic treatment was associated with a 72.5% decrease in bleeding rates. Pharmaceutical Business Review Online
(2/28)
- Roche agrees to release clinical trial studies
Swiss pharmaceutical firm Roche Holding has agreed to establish a procedure for releasing data from its clinical trials, including trials involving its highly successful flu medicine Tamiflu. The company will use a process that enables access to trial data without compromising patient confidentiality or publishing misleading results, according to pharmaceuticals unit head Daniel O'Day. Earlier, British company GlaxoSmithKline agreed to publish its own clinical study reports and trial results. Reuters
(2/27)
 |
|  |
| The Buzz(CORPORATE ANNOUNCEMENTS)
ISBT 128 Cell Therapy Update
STEMSOFT™ Software Inc. and Digi-Trax® Corporation are pleased to announce the certified integration of the HemaTrax®-CT labeling system into StemLab’s™ leading cellular therapy software to produce ISBT 128 compliant, on demand CT labels. Learn more about how we can help you adopt ISBT 128 in your cell therapy facility today.
| |
 |
|  |
| Government & Regulatory | | |
|
| Association News | | |
|
-
AABB releases rates for 2013 Annual Meeting and CTTXPO
AABB has released the registration and housing rates for the 2013 Annual Meeting and CTTXPO, which will be held in Denver. Registration and housing opens June 5 for AABB members and June 26 for general attendees. More information is available online.
| SmartQuote | | |
|
 | Mediocrity knows nothing higher than itself, but talent instantly recognizes genius."
--Sir Arthur Conan Doyle,
Scottish-born writer
|
| |
| |
|
Read more at SmartBrief.com |
|
A powerful website for SmartBrief readers including:
|
|
|
|
| |
| |
| | Recent AABB SmartBrief Issues:
- Thursday, February 28, 2013
- Wednesday, February 27, 2013
- Tuesday, February 26, 2013
- Monday, February 25, 2013
- Friday, February 22, 2013
| | | Lead Editor: Tom Parks
Managing Editor: Jennifer Garfinkel
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2013 SmartBrief, Inc.® Legal Information |
|
